our today’s good Priyam provide We outlook. we look will to business launches. on will afternoon discuss the upcoming at Thank product and first more and a quarter, our give you review call, evening you, performance everyone. trends, the today. updates then financials, our And appreciate John us or strategy for On and detailed joining product
joined warm Atimetrix, was welcome and an a leadership will more Joe part XX and including over be growth Specific Chief our retirement. years extending last a financial GenMark recently, start the integral team to diagnostics like sciences John the I through trajectory, X incredible He wish company retirement. missed, and Driscoll the following Akoya’s Joe John and of succeeds an his him well-deserved IPO. Diagnostics. success guided years wonderful Ek John leading I’d brings Officer including Financial as most by and Akoya’s than who leadership industries, to across operational in companies and life like of March.
legal Additionally, activities. executive a be She new the General we Kamocsay of will vital oversee all will as the Counsel. the our company’s appointment team member and Jennifer announced leadership of
on move our briefly performance let in So to summarize QX. me
the milestone This had X,XXXth company. very placement was field April. Akoya to our strong major XXXX, a in a start of the by the for highlighted instrument in
year. million XX% growth We over $XX.X quarter, first the of reported prior for also record the a revenue
delivering biology, is ultimately, the growth robust the and, early spatial products and translational portfolio full to the continuum clinical leadership of in from market that continued discovery of Our opportunities of a markets. services spans byproduct our
range an and end-to-end success each purpose-built sustained both unique Now segments important broad achieving the is with products core type. market is, customer diversity differentiator growth. and a company foundation this the of solutions, range valuable with we to strong for serve Akoya. complete and fundamentals of long-term needs a provide across the and That of for This are near-term
of A publications and our ongoing platforms. the and rapid predictor key current of success of featuring our demonstration is continued Akoya’s growth
XX, from of XX% now solutions, growth are XXX a March publications featuring period. prior there As the our year
sequential We million reported XX% other quarter-over-quarter Additional of highlights growth, success in $X.X quarter services include continued the revenue in largest $X.X lab in year-over-year revenue, growth revenue, the our reagent XX% service business. driven million a reagent and a quarterly by for the history. Akoya’s and
Prior initiated our strategy multiyear our to forthcoming I want to review initiatives, and following a minute in reviewing to strategic reiterate Akoya’s April of spend XXXX. IPO
market discovery in biology leader diagnostics. Our from establish to the as primary spatial to goal was Akoya
to phases strategy. X there’s Now this
first following included and IPO lasted and the distinct objectives. end XXXX The of initiated phase through was strategic the three
made portfolio solutions in to the discovery, serve the deliver instruments develop a translational and of following and R&D complete markets. and First, investments to we clinical immediate IPO, and industry-leading
the revenue organization Second, immediately capitalize launches we product growth. these expanded scale, drive the systems to have expertise, in our place SG&A the the on and to processes to
and we penetrating of we this, achieve our clinical all phase the to accounts, successfully set our of Third, on spatial our first And by organization large foundation TAM. solidified the clinical to portfolio biology the goal product strategy. readiness executed long-term our the of
Fusion of growth. And our lab successfully QX our new IPO drivers Specifically, we partnership. April products year. launched expanded like and ahead this culminating in business CLIA first of of as revenue companion launched we achieved delivered growth We quarter the key solid through and of this our diagnostic services certification, every expectations XXXX since in
execution. X,XXX instruments and most and the highlight Our XXX R&D nearly are the that obvious performance, field, solid publications revenue in metrics our commercial
from And now embarking second on objectives of to in the the the are second the phase following. discovery of XXXX, spatial diagnostics. strategy multiyear in And we phase include to this underway, now biology lead
priorities, with operational also scale growth. at top-line targeting robust to will First, our on now leverage continuing deliver while on we and focus strategic by deliver investments our limiting organization improving our a to
Second, in our system R&D workflow consumable revenue and initiatives we’re drive improvements on that solutions and reagent increases pull-through. focusing
We margins. these expect an high-margin reagents that driving overall will growing a our contribute total gross of in revenue, our percentage increase
cash like lab and begin spatial Agilent Third, development we our clinical will to expand in and on strategy key XXXX, in services growth opportunity. to market. the advancing positivity to address our top-line of second deliver Aquabona market the be continue our high to and with and clinical The clinical sustained focus will on advancing partnerships success to goal phase this margins, of achieve expanding increasing efforts, significant flow
product walk through goal continued roadmap with workflow for this me of So year and consumable simplification the now let revenue our growth.
We improvements and have and instruments, for reagents, across software. coordinated priorities investments
Fineco that with menu and will our an expanded our panels We reagent drive system expect and in Discovery increase Signature plex, pull-through. utilization,
on from will both HT customers’ upgrades our utilization hardware simplify reduce contributing and answer. PhenoCycler-Fusion further workflows software to ecosystem And also planned time will our the data and of to partners and the our growth. Our expanding pull-through
each Let reagent starting in these, our of on me more first, strategy. talk detail with
PhenoCode our this the include the PhenoCode the and high-flux throughout menu high-throughput These The HT. have reagent discovery reagent PhenoCycler-Fusion year states. our launch HT panels for the discovery PhenoCycler-Fusion PhenoImager for fall PhenoCode discovery the with for our brand PhenoImager panels rolling biomarker translational and expanding are panels signature and ready-made for under We panels both panels will for a XXXX.
designed panels Akoya including next immune panels fashion own The or needed. this X launched antibodies are The also catalog year’s XX providing of additional at XX second half our These AACR. customers them on the first as ability combine modular was were this a panel in profiling throughout of the to to focused launched while markers, year. their
HT. the PhenoCode For we’re clinical for PhenoImager the markets, launching panels translational signature X
and accelerate the half trials. deployment includes scalable clinical the higher launched The fast created of two signature on These for that and this advancing per HT assay first landscape sample rapidly enable next to panels and three X,XXX immuno-oncology due are were therapy and system. The our were and utilization nearly development in second ongoing in revenue panels panels year. the QX
high-value systems all our these across of reagent we’re panels, improvements making our workflow launch simplify workflows. accelerate continued the and of to With also
more field samples, per As samples for samples processing of planned on This includes customers. to discussed, the second to an to RNA software upgrade deliver support the from or multi-slide upgrade increase will also for X.X necessary which hardware week. effectively approximately throughput to and upgrade and is for in doubles on the quarter PhenoCycler-Fusion. This used be our includes carrier per the XX parallel previously up Fusion the workflow simplification components scope XX tissue instrument system a and Bio-Techne’s week throughput fusion
mid-XXXX, HT clinical moves simplify to efforts introduce to our continuing informatics plan we are we and true steps streamline HT, that post-processing In workflow directly and and a analysis translational post-processing PhenoImager improvements and demand further the workflow in HT On throughput The to tissue the clinical will a real-time customers’ turnaround supports and severalfold and our our postprocessing to on-instrument onto the drive standardized the reduction result image for a This be time. computing. standardization. upgrade for rapid and to standard.
our streamlining menu three content to increased use. drive are necessary of improvements our workflows Expanding out two and the system
is and advance to piece. continue solutions final and software our the analysis data We improve
two proving assumptions As our absolutely we grounded discussed, is have in software strategy that true. are
powerful new is analysis expanding biology data from academia. spatial and both rapidly of many solutions introduction driving First, the industry market the
the our benefit ensure customers with with we these partner groups most platforms. Our to compatibility if can
partners solution serve are range spent Second, better our resources enabling broad single a a that needs. building must of customer versus these
platforms gigabytes leverage called technology file that And a processing an QPT. standardized bioformat from and file to image XX-fold to on-instrument terabytes Akoya’s you, sizes remind reduces by into compression
through solutions. a an cloud the partner the is specifically to datasets. Enable optimized PhenoCycler a novel third-party newest development member AACR, now format for commercializing data of software and ecosystem, ease At Enable accelerate technology this platform of of proprietary this Medicine. and software transfer Now standardized help we simplify enables announced
platform. To-date, they cell it a or to a go Enable of analyzed a instead customers as XX,XXX the phenotypes or have as package, over of already the on solution robustness, minutes data Cloud to hours Available to weeks. accelerate Akoya’s ability insights software established days having from samples in will platform’s
with like Visiopharm, Indicalabs, PathAI, to have we industry partnered leaders established Oracle also and addition In other partnership, Bio. this
discovery the translation-owned software continued markets. the additional ongoing clinical expect growth We of spur solutions, spatial will biology developments of
addition ADS. downstream our PhenoImager In continue and Lab, discovery upstream or the Advanced we leveraging markets, market, translational to great progress CLIA Biopharma diagnostic make and Solutions, the clinical to HT the in
Our our partnership pipeline. biopharmaceutical and engagements driving with ABS customer expanding has groups generated Agilent precision meaningful medicine already with top
endometrial, to In clinical initial and anticipates urothelial open-label agreement data addition, spatial diagnostics ovarian, commercialize trial half exclusively co-develop multicenter of first-of-its-kind patients continues the and the advance. that during Acrivon from companion signature our XXXX. X it second cancer announced to with Acrivon a with Therapeutics in recently partner-resistant Phase
to throughout following we’re focused XXXX. the of review, Now on initiatives the rest
improvements the deliver continue translational on drive pull-through recent the new PhenoCycler-Fusion clinical applications and for market First, to discovery the and and PhenoImager to the workflow speed HT markets. the increase in further
the leading drive CROs, and PhenoImager Second, diagnostic continue and diagnostic and medical adoption with translational to to of leaders research clinical the partner markets. centers, biopharma, the HT
with targeted team, and limited Finally, forward drive we expanded the cash make achieve will leadership and operational of our positivity to support investments in new XXXX. going flow efficiencies and
I Now to over results. discuss Johnny? the with will call our Johnny now that, turn financial to
